Aleglitazar

N/A

Report date: 2022/01/14 13:23:58
NME

Base Information

Drug NameAleglitazar
Drug Alias NameAleglitazarum阿格列扎R-1439RG1439RO-0728804
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionPeroxisome proliferator activated receptor agonistsPeroxisome proliferator-activated receptor γ agonistsPeroxisome proliferator-activated receptor α agonists
TargetsPeroxisome proliferator activated receptorPeroxisome proliferator-activated receptor γPeroxisome proliferator-activated receptor α
Therapy Area/IndicationsDiabetes Mellitus, Type 2Acute Coronary SyndromeCardiovascular Diseases +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBulgariaCanada +[48] 
CombinationsNo
Global Highest StatusDiscontinued (Phase 3 Clinical)
Highest Status in ChinaDiscontinued
Originator CompaniesF. Hoffmann-La Roche Ltd
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesF. Hoffmann-La Roche LtdShanghai Roche Pharmaceuticals Ltd
Active IndicationsN/A
Inactive IndicationsDiabetes Mellitus, Type 2Acute Coronary SyndromeCardiovascular Diseases +[4] 

Other Information

ATC CodeN/A
Related LinksWikipediaDrugBankKEGG